Suppr超能文献

胸腺嘧啶或胸腺嘧啶核苷与1-(2-四氢呋喃基)-5-氟尿嘧啶及5-氟尿嘧啶联合给药对抗肿瘤活性的影响。

Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.

作者信息

Fujii S, Kitano S, Ikenaka K, Fukushima M, Nakamura H, Maehara Y, Shirasaka T

出版信息

Gan. 1980 Feb;71(1):100-6.

PMID:6769735
Abstract

The antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) on sarcoma was enhanced by oral coadministration of uracil, thymine, or thymidine. The activity was enhanced equally by thymine and by uracil than by thymidine, but thymine caused loss in body weight. The antitumor activity of 5-fluorouracil (5-FU) was also enhanced by thymine or uracil, but both caused loss in body weight. Degradation of 5-FU in vitro was inhibited more by thymine than by uracil. Phosphorylation of 5-FU, however, was not inhibited by uracil, thymine, or thymidine, even at 100 times the concentration of 5-FU. These results suggest that the mechanism of enhancement of the antitumor activity of FT-207 by thymine or thymidine was similar to that by uracil, and that uracil had more effect than thymine or thymidine in enhancing antitumor effect of these drugs to FT-207 without toxicity.

摘要

口服联合给予尿嘧啶、胸腺嘧啶或胸腺核苷可增强1-(2-四氢呋喃基)-5-氟尿嘧啶(FT-207)对肉瘤的抗肿瘤活性。胸腺嘧啶和尿嘧啶对该活性的增强作用相当,且强于胸腺核苷,但胸腺嘧啶会导致体重减轻。胸腺嘧啶或尿嘧啶也可增强5-氟尿嘧啶(5-FU)的抗肿瘤活性,但二者都会导致体重减轻。胸腺嘧啶对5-FU体外降解的抑制作用强于尿嘧啶。然而,即使尿嘧啶、胸腺嘧啶或胸腺核苷的浓度为5-FU的100倍,也不会抑制5-FU的磷酸化。这些结果表明,胸腺嘧啶或胸腺核苷增强FT-207抗肿瘤活性的机制与尿嘧啶相似,且尿嘧啶在增强这些药物对FT-207的抗肿瘤作用方面比胸腺嘧啶或胸腺核苷更有效,且无毒性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验